VNQI vs XBI
Vanguard Global ex-US Real Estate ETF vs SPDR S&P Biotech ETF
- • VNQI has the lower expense ratio at 0.12% vs 0.35% for XBI.
- • VNQI pays a higher dividend yield (5.06%).
Side-by-side metrics
| Metric | VNQI | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.12% | 0.35% |
Dividend yield Trailing 12-month yield. | 5.06% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $3.53B | $10.92B |
YTD return | -3.75% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.92 | 1.01 |
P/E ratio | 10.97 | — |
Last price | $43.44 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VNQI top holdings
| GMG.AX | Goodman Group | 3.83% |
| 8802.T | Mitsubishi Estate Co Ltd | 2.75% |
| 8801.T | Mitsui Fudosan Co Ltd | 2.52% |
| 0016.HK | Sun Hung Kai Properties Ltd | 2.07% |
| EMAAR.AE | Emaar Properties PJSC | 1.96% |
| 8830.T | Sumitomo Realty & Development Co Ltd | 1.89% |
| 1925.T | Daiwa House Industry Co Ltd | 1.69% |
| SGRO.L | Segro PLC | 1.53% |
| VNA.DE | Vonovia SE | 1.40% |
| SCG.AX | Scentre Group | 1.26% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VNQI
VNQI (Vanguard Global ex-US Real Estate ETF) is Non-US REITs and real estate companies globally. Managed by Vanguard, the fund carries $3.5B in assets under management, an expense ratio of 0.12%, a dividend yield of 5.06%. Its largest holding is Goodman Group (GMG.AX), which represents 3.8% of the portfolio. Real Estate is the fund's largest sector exposure at 98.7%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.